An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

Study Title

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

Teva Identifier

TV48125-CNS-30068 | 2017-002441-30

ClinicalTrials.gov Identifier

NCT03308968

Study Status

Completed

Trial Condition(s)

Migraine Prophylaxis

Interventions

Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 70 Years

Trial Duration

October 13, 2017 - May 29, 2019

Phase

Phase 3

Study Type

Interventional